MA42743A1 - Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f - Google Patents

Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Info

Publication number
MA42743A1
MA42743A1 MA42743A MA42743A MA42743A1 MA 42743 A1 MA42743 A1 MA 42743A1 MA 42743 A MA42743 A MA 42743A MA 42743 A MA42743 A MA 42743A MA 42743 A1 MA42743 A1 MA 42743A1
Authority
MA
Morocco
Prior art keywords
antibody molecules
tnf
alpha
specificity
multispecific antibody
Prior art date
Application number
MA42743A
Other languages
English (en)
Inventor
Stevan Graham Shaw
Diane Marshall
Sam Philip Heywood
Ralph Adams
Pallavi Bhatta
Emma Dave
David Paul Humphreys
Daniel Lightwood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA42743A1 publication Critical patent/MA42743A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'anticorps multispécifiques pour tnf alpha, il-17a et il-17f, des utilisations thérapeutiques de ces molécules d'anticorps et des procédés pour la production desdites molécules d'anticorps.
MA42743A 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f MA42743A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522391.0A GB201522391D0 (en) 2015-12-18 2015-12-18 Antibody molecules
PCT/EP2016/080979 WO2017102830A1 (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Publications (1)

Publication Number Publication Date
MA42743A1 true MA42743A1 (fr) 2019-07-31

Family

ID=55311227

Family Applications (2)

Application Number Title Priority Date Filing Date
MA044061A MA44061A (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
MA42743A MA42743A1 (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA044061A MA44061A (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Country Status (26)

Country Link
US (1) US20200277366A1 (fr)
EP (1) EP3390445A1 (fr)
JP (1) JP2019502380A (fr)
KR (1) KR20180089514A (fr)
CN (1) CN108473568A (fr)
AR (1) AR107735A1 (fr)
AU (1) AU2016369307A1 (fr)
BR (1) BR112018011860A2 (fr)
CA (1) CA3007493A1 (fr)
CL (1) CL2018001660A1 (fr)
CO (1) CO2018006667A2 (fr)
EA (1) EA201891446A1 (fr)
EC (1) ECSP18054047A (fr)
GB (1) GB201522391D0 (fr)
IL (1) IL259645A (fr)
MA (2) MA44061A (fr)
MX (1) MX2018007289A (fr)
PE (1) PE20181625A1 (fr)
PH (1) PH12018501141A1 (fr)
RU (1) RU2018126318A (fr)
SG (1) SG11201804803WA (fr)
TN (1) TN2018000200A1 (fr)
TW (1) TW201726731A (fr)
UY (1) UY37035A (fr)
WO (1) WO2017102830A1 (fr)
ZA (1) ZA201803681B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
JP7525499B2 (ja) * 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
GB201919061D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
CN114621354A (zh) * 2020-12-11 2022-06-14 正大天晴药业集团股份有限公司 Fab-白蛋白结合肽融合蛋白及其制备方法和应用
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
CN117642423A (zh) * 2021-09-13 2024-03-01 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途
WO2025248017A1 (fr) * 2024-05-31 2025-12-04 UCB Biopharma SRL Procédé de purification de protéines de recombinaison

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
UY34410A (es) * 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
EP3027649B1 (fr) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Anticorps bispécifiques tnfa-il-17

Also Published As

Publication number Publication date
IL259645A (en) 2018-07-31
SG11201804803WA (en) 2018-07-30
JP2019502380A (ja) 2019-01-31
WO2017102830A1 (fr) 2017-06-22
GB201522391D0 (en) 2016-02-03
MA44061A (fr) 2018-10-24
US20200277366A1 (en) 2020-09-03
PE20181625A1 (es) 2018-10-11
AU2016369307A1 (en) 2018-07-12
KR20180089514A (ko) 2018-08-08
CN108473568A (zh) 2018-08-31
RU2018126318A (ru) 2020-01-20
MX2018007289A (es) 2018-09-28
CO2018006667A2 (es) 2018-07-10
BR112018011860A2 (pt) 2018-12-04
EA201891446A1 (ru) 2018-11-30
RU2018126318A3 (fr) 2020-05-20
CL2018001660A1 (es) 2018-10-19
ECSP18054047A (es) 2018-07-31
EP3390445A1 (fr) 2018-10-24
CA3007493A1 (fr) 2017-06-22
TN2018000200A1 (en) 2019-10-04
ZA201803681B (en) 2019-09-25
AR107735A1 (es) 2018-05-30
UY37035A (es) 2017-07-31
PH12018501141A1 (en) 2019-01-28
TW201726731A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
PH12018501141A1 (en) Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PH12019502283A1 (en) Anti-lag3 antibodies
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MA34907B1 (fr) Molécules d'anticorps se liant à il-17a et il-17f
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MA35724B1 (fr) Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
MX375524B (es) Anticuerpos anti-axl.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PH12020551791A1 (en) Methods for the production of methacrylates
EP3415628A4 (fr) Micro-organisme mutant recombinant présentant une capacité de production d'acide malonique et procédé de production d'acide malonique l'utilisant
EA201691677A1 (ru) Генетические локусы, связанные с повышенной фертильностью у маиса
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
MA38475B1 (fr) Protéines spécifiques de baff et b7rp1 et leurs utilisations
PH12016500525A1 (en) Substituted phenylalanine derivatives
MX379715B (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso.
MX2020012065A (es) Compuestos de ciclopentano.
MX2018007221A (es) Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa).
EA201991474A1 (ru) Способы получения фитоина